Skip to main content
INTS
NASDAQ Life Sciences

Intensity Therapeutics Q3 2026: Cash Falls to $8.5M, Going-Concern Doubt Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.25
Mkt Cap
$11.427M
52W Low
$3
52W High
$15.748
52W Position info
8.3% above low
Off High info
79% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

INTS is trading near its 52-week low of $3 (8.3% above the low) on light trading volume (0.3× avg).

Summary

Intensity Therapeutics ended Q3 2026 with $8.5 million in cash and repeated its going-concern warning, while reporting 71% pCR in the INVINCIBLE-4 breast cancer study and resuming Phase 3 sarcoma enrollment.


Key Events · Earnings and Guidance · INTS

  • Q3 Net Loss Widens to $3.5M

    Net loss was $3.5 million for Q3 2026 versus $2.7 million a year earlier; nine-month loss reached $9.0 million. R&D rose 56% to $2.4 million on resumed INVINCIBLE-3 activity and new manufacturing.

  • Cash Falls to $8.5M, Going-Concern Doubt

    Cash and equivalents were $8.5 million at September 30, 2026, down from $11.9 million at December 31, 2025, after $6.7 million of operating cash burn. Management states substantial doubt about the ability to continue as a going concern absent new capital.

  • ATM Is the Only Funding Source

    The company sold 350,242 shares under its ATM for $1.5 million net in Q3 2026 and has $56.9 million of capacity remaining under the $60.0 million program. Cumulative ATM proceeds are $14.5 million on 2,009,329 shares.

  • INVINCIBLE-4 Shows 71% pCR

    Preliminary data from 14 patients showed 71% pCR in Cohort A (INT230-6 plus standard of care) versus 42% in Cohort B, with a 44% reduction in grade 3 adverse events. An IDMB safety review update is expected in Q1 2027.


Analysis · INTS · Life Sciences

Cash fell to $8.5 million from $11.9 million at year-end 2025, and the company burned $6.7 million on operations over nine months. Management again states substantial doubt about continuing as a going concern. The only funding source is the ATM, which has $56.9 million of capacity left but has been used at prices far below the $20.00 October 2025 offering — Q3 sales of 350,242 shares raised just $1.5 million net. Against that, the INVINCIBLE-4 breast cancer data (71% pCR in Cohort A vs 42% for standard of care) is the most encouraging clinical readout disclosed to date, and INVINCIBLE-3 sarcoma enrollment restarted in Q3. The thesis hinges on whether the company can raise enough capital to fund the Phase 3 trial before cash runs out.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INTS was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $3.00 to $15.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INTS - Latest Insights

INTS
Nov 05, 2026, 7:45 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.63 info
Change: -$0.620 (-19%) info
Market Cap: $8.253M info
INTS
Aug 11, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $4.19
Real-time Price: $2.63 info
Change: -$1.56 (-37%) info
Market Cap: $8.253M info
INTS
Aug 11, 2026, 7:17 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $2.63 info
Change: -$1.56 (-37%) info
Market Cap: $8.253M info
INTS
Jun 16, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $2.63 info
Change: -$1.08 (-29%) info
Market Cap: $8.253M info
INTS
May 07, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $2.63 info
Change: -$2.48 (-49%) info
Market Cap: $8.253M info